The First Biosimilar Drug in Breast Cancer Will Contribute 130 Million TL to the Capital Budget Per Year
Abdi Ibrahim, the leader of the Turkish pharmaceutical industry, has launched the first biosimilar product with the active ingredient Trastuzumab, which is now used in breast cancer among women. The product, which is also covered by the Ministry of Health, will provide a public contribution of 130 million TL in a year. The product that prevents the growth of tumor mass in patients with breast cancer will be the first biosimilar monoclonal antibody to be used by medical oncology.
Acıbadem Maslak Hospital Nutrition and Diet Specialist Özge Öçal listed the nutrients that should be considered in the fight against bre...
Memorial Antalya Hospital Infectious Diseases Department Specialist Dr. Şirin Elmi listed 8 situations that you should wash your hand.